Two experimental vaccines developed specifically against the Bundibugyo Ebola virus are expected to begin phase 2 clinical trials next week in the Democratic Republic of the Congo (DRC), the World Health Organization (WHO) said on Tuesday.
Speaking at a WHO news conference in Geneva, Dr Meg Doherty said both candidates received approval last week to advance to phase 2 of the Tumani randomised controlled trial.
The first vaccine, ChAdOx1, was developed by Oxford University and the Serum Institute of India, while the second was developed by US biotechnology company Moderna.
“Both of them last week were provided approval to move into phase two,” Doherty said.

Testing is expected to begin on November 26 or 27 in Bunia, where the trial is being conducted.
The second phase will assess the vaccines’ safety and immunogenicity, or their ability to trigger an immune response, she said.
Candidates that meet the required criteria will advance to phase 3, where researchers will evaluate their effectiveness against a comparator.
Over 140 participants
The Tumani trial, launched on October 23, is designed to accommodate additional vaccine candidates as they become available.
More than 140 participants have already enrolled in the broader trial, with thousands more expected to take part as researchers expand testing to additional sites and deploy mobile teams, according to Doherty.

WHO Director-General Tedros Adhanom Ghebreyesus also highlighted the progress in vaccine development amid the ongoing Ebola outbreak.
“We expect two candidate vaccines developed specifically for Bundibugyo virus to begin testing as early as next week,” he said.
Tedros said the outbreak had surpassed 11,300 cases and 5,500 deaths, with between 400 and 500 new infections still being reported each week.
He warned that insecurity, attacks on health workers and delays in identifying infections continued to undermine efforts to contain the outbreak.
“Such attacks also discourage people from seeking care in an Ebola treatment centre,” he said.





















